Patents by Inventor Vera Brinks

Vera Brinks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
    Patent number: 11352626
    Abstract: Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: June 7, 2022
    Assignee: Wings Therapeutics, Inc.
    Inventors: Elisabeth Marlene Haisma, Marko Potman, Wouter Beumer, Vera Brinks
  • OLIGONUCLEOTIDES MATCHING COL7A1 EXON 73 FOR EPIDERMOLYSIS BULLOSA THERAPY
    Publication number: 20200399638
    Abstract: Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages.
    Type: Application
    Filed: January 17, 2020
    Publication date: December 24, 2020
    Inventors: Elisabeth Marlene Haisma, Marko Potman, Wouter Beumer, Vera Brinks
  • Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
    Patent number: 10563198
    Abstract: Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 18, 2020
    Assignee: WINGS THERAPEUTICS, INC.
    Inventors: Elisabeth Marlene Haisma, Marko Potman, Wouter Beumer, Vera Brinks
  • OLIGONUCLEOTIDES MATCHING COL7A1 EXON 73 FOR EPIDERMOLYSIS BULLOSA THERAPY
    Publication number: 20180216106
    Abstract: Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages.
    Type: Application
    Filed: March 11, 2016
    Publication date: August 2, 2018
    Inventors: Elisabeth Marlene Haisma, Marko Potman, Wouter Beumer, Vera Brinks